A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy

Immune checkpoint inhibitors, such as monoclonal antibodies targeting programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1), have achieved enormous success in the treatment of several cancers. However, monoclonal antibodies are expensive to produce, have poor tumor penetration, and may ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuanyuan, Gu, Tingxuan, Tian, Xueli, Li, Wenwen, Zhao, Ran, Yang, Wenqian, Gao, Quanli, Li, Tiepeng, Shim, Jung-Hyun, Zhang, Chengjuan, Liu, Kangdong, Lee, Mee-Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160380/
https://www.ncbi.nlm.nih.gov/pubmed/34054817
http://dx.doi.org/10.3389/fimmu.2021.654463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160380/
https://www.ncbi.nlm.nih.gov/pubmed/34054817
http://dx.doi.org/10.3389/fimmu.2021.654463

Ejemplares similares